Dimou Maria, Iliakis Theodore, Maltezas Dimitrios, Bitsani Aikaterini, Kalyva Sotiria, Koudouna Aspasia, Kotsanti Sotiria, Petsa Panayiota, Papaioannou Paraskevi, Kyrtsonis Marie-Christine, Panayiotidis Panayiotis
1st Propaedeutic Clinic, Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
1st Propaedeutic Clinic, Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Anticancer Res. 2018 Jul;38(7):4187-4191. doi: 10.21873/anticanres.12712.
BACKGROUND/AIM: Hematological malignancies are frequently complicated by secondary immunodeficiency (SID). Immunoglobulin replacement with intravenous gamma globulins (IVIg) reduces infection incidence, antibiotics' need and hospitalization days in these patients. Facilitated subcutaneous immunoglobulin replacement (fSCIg) has been studied in primary immunodeficiency patients and is equally efficacious with several advantages (self-administration, same bioavailability, long infusion intervals, fewer adverse drug reactions). fSCIg has been less extensively studied in SID. We present our retrospective single-center data of fSCIg administration to hematological patients with SID, focusing on efficacy and safety issues.
Overall, 33 hematological patients with hypogammaglobulinemia were treated with fSCIg according to ESMO 2015 guidelines, between mid-October 2015 and mid-January 2018 in our Department.
The infection rate was very low (18.1%). Shorter infusion intervals further reduced it. ADRs were rare (9%) and mild (grade 1). fSCIg managed to reduce the everyday nursery/hospital burden of our tertiary hospital.
fSCIg compares favorably to IVIg replacement in SID patients.
背景/目的：血液系统恶性肿瘤常并发继发性免疫缺陷（SID）。静脉注射丙种球蛋白（IVIg）进行免疫球蛋白替代治疗可降低这些患者的感染发生率、抗生素使用需求及住院天数。皮下免疫球蛋白简易替代疗法（fSCIg）已在原发性免疫缺陷患者中进行研究，其疗效相当且具有多项优势（可自我给药、生物利用度相同、输注间隔长、药物不良反应少）。fSCIg在SID中的研究较少。我们展示了对患有SID的血液系统患者进行fSCIg治疗的回顾性单中心数据，重点关注疗效和安全性问题。
2015年10月中旬至2018年1月中旬期间，我们科室共有33例低丙种球蛋白血症的血液系统患者按照ESMO 2015指南接受了fSCIg治疗。
感染率非常低（18.1%）。缩短输注间隔可进一步降低感染率。药物不良反应罕见（9%）且症状轻微（1级）。fSCIg成功减轻了我们三级医院日常的护理/医院负担。
在SID患者中，fSCIg与IVIg替代治疗相比具有优势。
